Abstract 4058
Background
For individual treatment planning in patients with metastatic castration resistant prostate cancer (mCRPC), molecular analyses are increasingly used. As most patients have bone only disease, bone biopsies are often the only source for tumour tissue. However, the success rate of computed tomography (CT)-guided bone biopsies for molecular analyses in mCRPC patients is only 36.5-44%. Positron emission tomography (PET) using 68Ga-PSMA is a promising tool to increase the success rate of bone biopsies for molecular analyses in mCRPC patients.
Methods
In this multicenter study, the success rate of 68Ga-PSMA guided bone biopsies for molecular diagnostics was retrospectively evaluated in a subset of mCRPC patients who underwent a bone biopsy for whole-genome DNA sequencing within the CPCT-02 study (NCT01855477). To evaluate whether biopsies were obtained from a 68Ga-PSMA positive lesion, rigid body image registration of 68Ga-PSMA PET/CT and interventional CT was performed. This technique provided volume of interest (VOI) based quantification of 68Ga-PSMA uptake at the exact biopsy site. In addition, the potential impact of molecular analyses on clinical decision making was evaluated.
Results
Sixty-nine 68Ga-PSMA-guided biopsies were eligible for primary analysis. Based on tumor percentage ≥ 30%, 70% of 68Ga-PSMA-guided biopsies was eligible for molecular analyses. At biopsy sites with positive, inconclusive or negative 68Ga-PSMA uptake, tumour percentage was ≥ 30% in 73%, 55% and 36% of the biopsies, respectively (p = 0.0850). At sites of biopsies with a tumour percentage ≥ 30%, standardized uptake value (SUV)max and SUVmean of 68Ga-PSMA were significantly higher (p = 0.0260 and p = 0.0129 respectively), whereas Hounsfield units (HU)mean and HUmax on CT were significantly lower (p = 0.0189 and p = 0.0494 respectively). Molecular analyses identified potentially targetable aberrations including PTEN loss, AR amplifications, and BRCA variants.
Conclusions
68Ga-PSMA PET/CT is a useful technique to improve the success rate of CT-guided bone biopsies for molecular analyses in mCRPC patients. Successful bone biopsies for molecular analyses can improve individual treatment planning by detecting targetable mutations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
R. de Wit: Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Sanofi; Advisory / Consultancy, Speaker Bureau / Expert testimony: Merck; Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy: Roche; Advisory / Consultancy: Janssen; Advisory / Consultancy: Clovis. N. Mehra: Advisory / Consultancy, Research grant / Funding (institution): Astellas; Advisory / Consultancy, Research grant / Funding (institution): Janssen; Research grant / Funding (institution): Pfizer; Advisory / Consultancy, Research grant / Funding (institution): Roche; Advisory / Consultancy, Research grant / Funding (institution): Sanofi Genzyme; Advisory / Consultancy: MSD; Advisory / Consultancy: BMS; Advisory / Consultancy: Bayer. A.A.M. Van der Veldt: Honoraria (institution), Advisory / Consultancy: BMS; Honoraria (institution), Advisory / Consultancy: MSD; Honoraria (institution), Advisory / Consultancy: Roche; Honoraria (institution), Advisory / Consultancy: Novartis; Honoraria (institution), Advisory / Consultancy: Pierre Fabre; Honoraria (institution), Advisory / Consultancy: Pfizer; Honoraria (institution), Advisory / Consultancy: Sanofi; Honoraria (institution), Advisory / Consultancy: Ipsen. M.P. Lolkema: Research grant / Funding (institution): JNJ; Research grant / Funding (institution): Astellas. All other authors have declared no conflicts of interest.
Resources from the same session
3073 - 1 patient 3 different advance Ca nurse’s roles: symptom management&continuum care through a joint approach in a clinical case
Presenter: Catarina Almeida
Session: Poster Display session 3
Resources:
Abstract
4527 - Identification of malnutrition risk factors in patients with cancer in the first nursing visit
Presenter: Amaia Valverde
Session: Poster Display session 3
Resources:
Abstract
2904 - Engaging Cancer Survivors, Healthcare Providers and Advocates in The Development of a Colorectal Cancer Survivorship Information Resource: A Participatory Action Research Study
Presenter: Amanda Drury
Session: Poster Display session 3
Resources:
Abstract
3435 - Medical nurses’ experiences of the care-needs of adult patients with a primary brain tumour
Presenter: Jamila Mohammed
Session: Poster Display session 3
Resources:
Abstract
857 - Feasibility and acceptability of a mHealth intervention to increase colonoscopy uptake among Chinese first-degree relatives: a pilot cluster randomized controlled trial
Presenter: Yang Bai
Session: Poster Display session 3
Resources:
Abstract
1087 - Cancer patient participation and compliance in microbiome sample collection: an oncology research nurse’s experience
Presenter: Julie Malo
Session: Poster Display session 3
Resources:
Abstract
2783 - Implementing Digital Individual Care plans for Patients with Head and Neck cancer- Challenges and opportunities
Presenter: Helena Ullgren
Session: Poster Display session 3
Resources:
Abstract
1152 - The Effect of the Short-term and Long-term Compassion Fatigue Resiliency Program on the Quality of Life, Perceived Stress and Psychological Resilience of Oncology-Hematology Nurses
Presenter: Tugba Pehlivan
Session: Poster Display session 3
Resources:
Abstract
1172 - Competing risk analyses of overall survival and cancer-specific survival in patients with orbital rhabdomyosarcoma after surgery: a large cohort study
Presenter: Yu Zhang
Session: Poster Display session 3
Resources:
Abstract
5949 - Communication of genetic information to family members in hereditary cancers and healthcare providers’ role
Presenter: Carla Pedrazzani
Session: Poster Display session 3
Resources:
Abstract